Two years of maintenance chemotherapy with rituximab resulted in improved progression-free survival among elderly patients with chronic lymphocytic leukemia.
Neoadjuvant treatment with dabrafenib and trametinib offered significantly improved event-free survival over standard of care in high-risk melanoma patients.
Patients with DNA mismatch repair-deficient/microsatellite instability-high metastatic colorectal cancer who received nivolumab along with ipilimumab had high response rates and improved survival outcomes compared with those who received nivolumab alone.
Researchers discovered that melanoma patients who received immunotherapy while taking a pan beta blocker lived longer than patients who received immunotherapy alone.
Some patients with unresectable or metastatic melanoma who receive immunotherapy and who continue therapy after progression have decreased tumor burden, and survival is improved when the therapy is continued as well, according to a new pooled analysis.
Undergoing cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy (HIPEC) resulted in improved overall survival compared with resection alone for patients with gastric cancer with peritoneal carcinomatosis, according to data presented at the 2018 Gastrointestinal Cancers Symposium.
Patients assigned to robot-assisted minimally invasive thoraco-laparoscopic esophagectomy had fewer overall, surgery-related, and cardiopulmonary complications compared with open transthoracic esophagectomy, according to the results of the ROBOT trial.
First-line ramucirumab in combination with chemotherapy significantly improved progression-free survival in patients with metastatic gastric or gastroesophageal junction adenocarcinoma, according to results of the RAINFALL trial.
Presence of germline TP53 variants predisposed children to acute lymphoblastic leukemia and was associated with adverse outcomes compared with children who did not have these variants, according to the results of a new study.
Use of oral contraceptives may be beneficial for chemoprevention for a range of women with different baseline cancer risks, according to the results of a new study.